96 Tests PN: A111413
Components:
45x Ab-conjugated beads (S5P9 - human IL-29 Ab-bead). PN: B111413A. One vial containing 100 µL of anti-human IL-29 conjugated to AimPlex Bead S5P9.
25x Biotin-detection Ab (human IL-29 Biotin-dAb). PN: B111413B. One vial containing 100 µL of biotinylated anti-human IL-29.
Lyophilized Standard Mix-Human Group 2 Panel B, 10-Plex. PN: HG20010. One vial containing lyophilized recombinant human IL-17F, IL-20, IL-21, IL-28A, IL-29, IL-33, M-CSF, MPO, TSLP, and VEGF-A. Note: If multiple analyte kits on the above target list are ordered as a panel, only one vial of standard mix is supplied for those analyte kits.
Application: Optimal antibody pair and antigen standard for assaying human IL-29. Can be multiplexed with other analytes in Human Group 2. To be used in conjunction with the AimPlex NR Basic Kit (PN: P100001) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.
Storage 2-8 C in the dark.
Important: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.
For Research Use Only. Not for use in diagnostic procedures.
Assay Specifications:
Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate
Sensitivity (LOD): < 5 pg/mL
Quantitation range:
LLOQ: < 10 pg/mL
ULOQ: > 5,000 pg/mL
Standard dose recovery: 70-130%
Intra-assay CV: < 10%
Inter-assay CV: < 20%
Cross-reactivity of analytes in Human Group 2: Negligible
Sample volume: 15 µL/test
Description:
Interleukin-29 (Accession Q8IU54) is one of three members of the IFN-λ subfamily within the IL-10 cytokine family. The others being IL-28A (IFN-λ2) and IL-28B (IFN-λ3), all also known as the Interferon III family. IL-29 is secreted by macrophages and dendritic cells. IL-29 has significant antiviral activity and immunoregulatory properties as it plays an integral role in host defenses against microbes. IL-29 has also has the ability to induce apoptosis and suppress proliferation of CD4+ T cells. There is also a correlation between patients with rheumatoid arthritis and IL-29 expression resulting in synovial inflammation, possibly indicating that it could act as a biomarker for the disease. IL-29 also shows to inhibit osteoclastogenesis and may be important to bone resorption.
References:
Vilcek J. Novel Interferons. Nat Immunol. 2003; 4(1): 8-9. Doi: 10.1038/ni0103-8.
Want F, Xu L, Feng X, Guo D, Tan W, Zhang M. Interleukin-29 modulates proinflammatory cytokine production in synovial inflammation of rheumatoid arthritis. Arthritis Research & Therapy. 2012; 14(5). Doi: 10.1186.ar4-67.